HYPERACUTE REJECTION IN AN EX-VIVO MODEL OF RENAL XENOGRAFTING - ROLEOF THE MEDIATOR RESPONSE AND ITS PHARMACOLOGICAL MANIPULATION BY THE SPECIFIC PLATELET-ACTIVATING-FACTOR ANTAGONIST WEB 2086BS

Citation
Dm. Saumweber et al., HYPERACUTE REJECTION IN AN EX-VIVO MODEL OF RENAL XENOGRAFTING - ROLEOF THE MEDIATOR RESPONSE AND ITS PHARMACOLOGICAL MANIPULATION BY THE SPECIFIC PLATELET-ACTIVATING-FACTOR ANTAGONIST WEB 2086BS, Transplantation, 57(3), 1994, pp. 358-363
Citations number
40
Categorie Soggetti
Immunology,Surgery
Journal title
ISSN journal
00411337
Volume
57
Issue
3
Year of publication
1994
Pages
358 - 363
Database
ISI
SICI code
0041-1337(1994)57:3<358:HRIAEM>2.0.ZU;2-6
Abstract
The pharmacologic modulation of the platelet-activating factor antagon ist WEB 2086BS on the release of metabolites of the arachidonic acid a nd the cytokine TNF alpha was investigated in an ex vivo xenograft mod el of hyperacute rejection. Pig kidneys were perfused for 60 min in a perfusion system with oxygenated heparinized human or autologous porci ne blood, respectively. During autologous perfusion, no alterations in the mediator response could be detected, whereas xenogeneic perfusion induced progressive release of mediators. Treatment by the platelet-a ctivating factor antagonist WEB 2086BS resulted in a significantly red uced liberation of the cytokine TNF alpha and of prostanoids. The hist ological findings verified that a hyperacute rejection in the xenogene ic perfused organs had occurred, which was mitigated by the treatment with WEB 2086BS. This observation confirms that inflammatory mediators play a decisive role in hyperacute xenogeneic rejection. The results suggest that suppression or manipulation of mediator-specific tissue r eceptors by receptor-antagonists could be an additional therapeutic mo de to control hyperacute rejection in xenogeneic transplantation.